Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Perspective Therapeutics, Inc.
organization7 mentionslast seen Nov 9, 2026
A radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.
Relationships 20
- Perspective Therapeutics, Inc.developsbamzireotide navoxetan99% confidence7 sources
- Perspective Therapeutics, Inc.develops[212Pb]PSV35999% confidence7 sources
- Perspective Therapeutics, Inc.developslapemelanotide zapixetar99% confidence6 sources
- Perspective Therapeutics, Inc.employsMarkus Puhlmann99% confidence5 sources
- Perspective Therapeutics, Inc.developstheranostic approach99% confidence4 sources
- Perspective Therapeutics, Inc.employsThijs Spoor99% confidence3 sources
- Perspective Therapeutics, Inc.employsJohan (Thijs) Spoor99% confidence2 sources
- Perspective Therapeutics, Inc.develops224Ra/212Pb generator platform99% confidence2 sources
- Perspective Therapeutics, Inc.employsJoel Sendek99% confidence2 sources
- Perspective Therapeutics, Inc.developsCCK2R8199% confidence2 sources
- Perspective Therapeutics, Inc.developsradiopharmaceutical therapy98% confidence2 sources
- Perspective Therapeutics, Inc.employsJohan Spoor97% confidence1 source
- Perspective Therapeutics, Inc.develops[212Pb]lapemelanotide zapixetar96% confidence1 source
- Perspective Therapeutics, Inc.partners withMerck95% confidence1 source
- Perspective Therapeutics, Inc.develops224Ra/212Pb generator93% confidence1 source
- Perspective Therapeutics, Inc.develops224Ra/212Pb generator92% confidence1 source
- Perspective Therapeutics, Inc.developsPSV59492% confidence1 source
- Perspective Therapeutics, Inc.partners withMerck92% confidence1 source
- Perspective Therapeutics, Inc.developsalpha-particle therapy90% confidence1 source
- MercksuppliesPerspective Therapeutics, Inc.90% confidence1 source
Relationship
Perspective Therapeutics, Inc.developslapemelanotide zapixetar
99% confidence6 supporting mentions
Either name opens that entity’s relationships.
Sources 6
- filingSEC EDGARNov 9, 2026Perspective Therapeutics, Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Meaningful antitumor activity observed for lapemelanotide zapixetar (VMT01) monotherapy in metastatic melanoma
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the Company is also developing complementary imaging techniques
- filingSEC EDGAROct 23, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma)
- filingSEC EDGAROct 8, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
advancing a portfolio of clinical-stage programs in the U.S., including lapemelanotide zapixetar (VMT01, melanoma)
- filingSEC EDGAROct 1, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
- filingSEC EDGARSep 14, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company is advancing a portfolio of clinical-stage programs in the U.S., including lapemelanotide zapixetar (VMT01, melanoma)